Skip to NavigationSkip to content

Gilead

NICE give go-ahead to Gilead's Yescarta for adults with lymphoma

The NHS cost effectiveness body NICE has approved Gilead’s Yescarta for treatment of come adults with lymphoma.

Gilead’s treatment will be funded through the Cancer Drugs Fund for adults with relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma, two aggressive subtypes of non-Hodgkin lymphoma.

Gilead's CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the latter’s reveal of data on rival Kymriah with study findings of its own CAR-T therapy Yescarta (Axicabtagene Ciloleucel).

The findings revealed that after a minimum follow-up of two years after a single Yescarta infusion – and a median follow-up of 27.1 months – 39% of participants achieved an ongoing response in the treatment of refractory large B-cell lymphoma; in this group, 93% of those experiencing response at 12 months went on to maintain a response after 24

NHS England appoves Gilead's CAR T therapy Yescarta

Gilead’s CAR T therapy Yescarta is set to be made available on the NHS in England for adults with aggressive non-Hodgkin lymphoma, it was announced today.

Although NICE rejected the £300,000 per patient treatment in August of this year, NHS England has come to a confidential agreement with Yescarta manufacturer Gilead Sciences.

Thus an estimated 200 patients a year could benefit from the personalised treatment according to NHS England.

Gilead to release generic versions of hep C meds over a decade before patent expiry

Gilead has announced its intention to undercut itself by releasing generic versions of its blockbuster drugs for the treatment of hepatitis C, Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir), more than a decade before their patents expire.

The company’s hep C portfolio generated $831 million in the second quarter of 2018, and the latter of the pair attracted controversy on its 2014 launch when its $1,150-per-pill price tag was revealed.

Gilead and Galapagos' ankylosing spondylitis drug hits Phase 2 trial goal

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase 2 trial investigating its efficacy in the treatment of moderately to severely active ankylosing spondylitis (AS) in adult patients.

Specifically, the therapy was found to lead to “significantly greater improvements” in AS Disease Activity Score (ASDAS) – the trial’s primary endpoint – after 12 weeks of treatment; the mean change of -1.5 versus -0.6 for placebo, while 76% of patients taking filgotinib achieved an ASAS response of 20 compared to

Novartis' CAR T therapy Kymriah to become available on the NHS

Novartis’ Kymriah is set to become the first CAR T therapy to become available on the NHS after it was revealed that the cancer treatment will be offered to children and young adults up to the age of 25 years old with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse.

While both Gilead and Novartis’ CAR T therapies were awarded marketing authorisation in the European Union just last week, NICE were quick to reject Gilead’s CAR T therapy Yescarta on the grounds that it was too expensive.

Novartis' Kymriah & Gilead's Yescarta become first EU-approved CAR T therapies

Almost one full year since the treatment was given a “historic” approval in the US, Novartis’ CAR T therapy Kymriah (tisagenlecleucel) has been awarded marketing authorisation in the EU for the treatment of blood cancer. Its rival, Gilead/Kite Therapeutics’ Yescarta (axicabtagene ciloleucel) has also been authorised, marking the first approval of its kind in the region.

As CAR-T therapies, both are manufactured from immune cells derived from a specific patient’s body.

Gilead CMO announces departure alongside two new exec appointments

Published on: 17/08/18

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

Gilead CMO announces departure alongside two new exec appointments

Gilead has announced that its Chief Medical Officer is to vacate the role after just five months and leave the company in order to “pursue another opportunity”.

Dr Andrew Cheng will remain at Gilead until 7 September to aid in the transition period.

Gilead's CEO and Chairman to both step down before year's end

Published on: 30/07/18

Gilead has announced that its President and Chief Executive Officer Dr John Milligan (pictured) will be stepping down by the end of the year, ending his run of 28 years at the company. He will remain in the role while the Board of Directors searches for a successor.

Alongside him, it has also been revealed that Chairman Dr John Martin will also be leaving the company. He has said he will vacate his position on the Board when a replacement CEO has been found.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches